← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Spero Therapeutics, Inc.
Cambridge, MA
$18,155,709
Total funding
4
Grants
Funding over time
peak $6.1M · FY2017–24$10M$7.5M$5M$2.5M$0
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$12,273,444 · 3
DOD$5,882,265 · 1
By mechanism
N01$11,283,548 · 2
—$5,882,265 · 1
R44$989,896 · 1
Investigators at Spero Therapeutics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
DEVELOPMENT OF SPR206, A DIRECT ACTING POLYMYXIN ANTIBIOTIC WITH REDUCED NEPHROTOXICITY, TO TREAT MULTIDRUG-RESISTANT GRAM-NEGATIVE BACTERIAL PATHOGENS$5,882,265
· FY2019 · Defense Health Agency
Development of Therapeutic Products for Biodefense, AntiMicrobial Resistant (AMR) Infections and Emerging Infectious Diseases$3,424,537
N01 · FY2024 · AI
Advanced Development of Antibacterial Countermeasures$2,089,779
N01 · FY2021 · AI
Advanced Development of Antibacterial Countermeasures$1,901,006
N01 · FY2023 · AI
Advanced Development of Antibacterial Countermeasures$1,494,630
N01 · FY2023 · AI
Advanced Development of Antibacterial Resistance Countermeasures$1,386,775
N01 · FY2023 · AI
Optimizing Lead Therapeutic Compounds Against Infectious Diseases$571,132
N01 · FY2018 · AI
A Novel Gyrase Inhibitor for the Treatment of Drug-susceptible and Multidrug-resistant Mycobacterium tuberculosis Infections$564,718
R44 · FY2017 · AI
A Novel Gyrase Inhibitor for the Treatment of Drug-susceptible and Multidrug-resistant Mycobacterium tuberculosis Infections$425,178
R44 · FY2018 · AI
Optimizing Lead Therapeutic Compounds Against Infectious Diseases$210,895
N01 · FY2019 · AI
Advanced Development of Antibacterial Countermeasures$104,638
N01 · FY2023 · AI
Advanced Development of Antibacterial Countermeasures$34,083
N01 · FY2023 · AI
Advanced Development of Antibacterial Countermeasures$29,823
N01 · FY2023 · AI
Advanced Development of Antibacterial Countermeasures$21,302
N01 · FY2023 · AI
Advanced Development of Antibacterial Countermeasures$14,948
N01 · FY2023 · AI